Home Cart Sign in  
Chemical Structure| 603148-36-3 Chemical Structure| 603148-36-3

Structure of Azeliragon
CAS No.: 603148-36-3

Chemical Structure| 603148-36-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Azeliragon is an orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE) with Kd of 12.7 nM for human recombinant sRAGE. While RAGE transports amyloid-β (Aβ) from plasma into the CNS, Azeliragon is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).

Synonyms: TTP488; PF-04494700

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Azeliragon

CAS No. :603148-36-3
Formula : C32H38ClN3O2
M.W : 532.12
SMILES Code : CCN(CC)CCCOC1=CC=C(C2=CN(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)C(CCCC)=N2)C=C1
Synonyms :
TTP488; PF-04494700
MDL No. :MFCD11977600
InChI Key :KJNNWYBAOPXVJY-UHFFFAOYSA-N
Pubchem ID :11180124

Safety of Azeliragon

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) and is currently under development as a treatment option to potentially slow the progression of mild Alzheimer’s disease (AD)[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
4175 and 4T1 cells 1 µM 24 hours To evaluate the effect of RAGE inhibitors on cell invasion and migration, results showed that Azeliragon significantly reduced invasion and migration of 4175 and 4T1 cells NPJ Breast Cancer. 2023 Jul 13;9(1):59.
4T1 cells 0.05–1 μM 24, 48, 72 hours To evaluate the effect of RAGE inhibitors on cell proliferation and viability, results showed that Azeliragon and FPS-ZM1 did not affect cell proliferation or viability in vitro NPJ Breast Cancer. 2023 Jul 13;9(1):59.
MDA-MB-231/4175 cells 0.05–1 μM 24, 48, 72 hours To evaluate the effect of RAGE inhibitors on cell proliferation and viability, results showed that Azeliragon and FPS-ZM1 did not affect cell proliferation or viability in vitro NPJ Breast Cancer. 2023 Jul 13;9(1):59.
Human umbilical vein endothelial cells (HUVECs) 1 to 5 μmol/L 12 hours To evaluate the effect of the RAGE antagonist Azeliragon (TTP488) on AGE-mediated KLF2 suppression. Results showed that TTP488 prevented the suppression of KLF2 mRNA by CML-BSA with an EC50 of 1.9 μmol/L. J Am Heart Assoc. 2018 Jan 4;7(1):e007566.
Pan02 cells 0.05–3 µM 24 hours To evaluate the effect of Azeliragon on the proliferation of Pan02 cells, results showed that Azeliragon inhibited cell proliferation in a dose-dependent manner Cancers (Basel). 2024 Dec 24;17(1):17.
Panc1 cells 0.05–3 µM 24 hours To evaluate the effect of Azeliragon on the proliferation of Panc1 cells, results showed that Azeliragon inhibited cell proliferation in a dose-dependent manner Cancers (Basel). 2024 Dec 24;17(1):17.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice 4175/NSG orthotopic xenograft model Intraperitoneal injection 1 mg/kg Twice weekly until tumor volume reached ~500 mm³ To evaluate the effect of Azeliragon on tumor growth and metastasis, results showed that Azeliragon significantly reduced lung metastasis NPJ Breast Cancer. 2023 Jul 13;9(1):59.
Mice ApcMin/+ mouse model Oral 4 mg/kg Not specified To evaluate the inhibitory effect of Azeliragon on tumor growth and MDSC infiltration, results showed Azeliragon significantly suppressed tumor growth and reduced MDSC infiltration. Gut. 2025 Jan 17;74(2):214-228.
C57BL/6 mice GL261 glioma model Intraperitoneal injection 0.2 mg/kg Once daily for 25 days To evaluate the therapeutic effect of Azeliragon on glioblastoma, the results showed that Azeliragon treatment significantly improved the survival rate of mice and reduced tumor proliferation. Theranostics. 2025 Jan 1;15(2):726-744
NU/NU mice and C57BL/6NJ mice Pancreatic cancer model Intraperitoneal injection 1 mg/kg Daily administration until mice survived To evaluate the anti-tumor activity of Azeliragon alone or in combination with radiation therapy in pancreatic cancer mouse models, results showed that Azeliragon alone or in combination with RT significantly delayed tumor growth and prolonged survival Cancers (Basel). 2024 Dec 24;17(1):17.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05986851 Glioblastoma PHASE2 ACTIVE_NOT_RECRUITING 2025-06-30 University of Colorado Anschut... More >>z Medical Campus, Aurora, Colorado, 80045, United States|Miami Cancer Institute - Baptist Health, Miami, Florida, 33176, United States|Corewell Health, Royal Oak, Michigan, 48073, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|Lenox Hill Hospital, New York, New York, 10021, United States|The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, 73104, United States|University of Utah Health Huntsman Cancer Center, Salt Lake City, Utah, 84112, United States|University of Washington, Seattle, Washington, 98109, United States Less <<
NCT05766748 Metastatic Pancreatic Cancer PHASE1|PHASE2 RECRUITING 2025-05-25 Cedars-Sinai Medical Center, S... More >>amuel Oschin Comprehensive Cancer Institute, Los Angeles, California, 90048, United States|Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, 33486, United States|Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, 97401, United States|AHN Cancer Institute - Allegheny General Hospital, Pittsburgh, Pennsylvania, 15212, United States|Prisma Health - Upstate, Greenville, South Carolina, 29605, United States|Texas Oncology - Northeast Texas, Tyler, Texas, 75702, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.40mL

1.88mL

0.94mL

18.79mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories